An Extensive Network of TET2-Targeting MicroRNAs Regulates Malignant Hematopoiesis

Cell Reports

Volumn 5, Issue 2, 2013, Pages 471-481

  Cheng, Jijun ^a,b   Guo, Shangqin ^a   Chen, Suning ^c   Mastriano, Stephen J ^a,b   Liu, Chaochun ^d   D'Alessio, Ana C ^g   Hysolli, Eriona ^a   Guo, Yanwen ^a,b   Yao, Hong ^c   Megyola, Cynthia M ^a,b   Li, Dan ^a,b   Liu, Jun ^a,b   Pan, Wen ^a,b   Roden, Christine A ^a,b   Zhou, Xiao Ling ^a,e   Heydari, Kartoosh ^b   Chen, Jianjun ^f   Park, In Hyun ^a   Ding, Ye ^d   Zhang, Yi ^g   Lu, Jun ^a,b   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d WADSWORTH CENTER   (United States)

^e SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^f UNIVERSITY OF CHICAGO   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 101; MICRORNA 125B; MICRORNA 29; MICRORNA 29B; MICRORNA 29C; MICRORNA 7; ONCOPROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA BINDING PROTEIN; TET2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC MARKER; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; RNA GENE; TET2 GENE; TRANSCRIPTION REGULATION; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; DOWN REGULATION; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; PATHOLOGY;

3' UNTRANSLATED REGIONS; ANIMALS; CYTOSINE; DNA-BINDING PROTEINS; DOWN-REGULATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; MICE; MICRORNAS; PHENOTYPE; PROTO-ONCOGENE PROTEINS;

EID: 84887021053     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.08.050     Document Type: Article

References (42)

1. Adams B.D., Guo S., Bai H., Guo Y., Megyola C.M., Cheng J., Heydari K., Xiao C., Reddy E.P., Lu J. An invivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response. Cell Rep. 2012, 2:1048-1060.
2. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
3. Betel D., Koppal A., Agius P., Sander C., Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010, 11:R90.
4. Chi S.W., Zang J.B., Mele A., Darnell R.B. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009, 460:479-486.
5. Cimmino L., Abdel-Wahab O., Levine R.L., Aifantis I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011, 9:193-204.
6. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Massé A., Kosmider O., Le Couedic J.P., Robert F., Alberdi A., et al. Mutation in TET2 in myeloid cancers. N.Engl. J. Med. 2009, 360:2289-2301.
7. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4:721-726.
8. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., Zanesi N., Kornblau S.M., Marcucci G., Calin G.A., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
9. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
10. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
11. Guo S., Lu J., Schlanger R., Zhang H., Wang J.Y., Fox M.C., Purton L.E., Fleming H.H., Cobb B., Merkenschlager M., et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc. Natl. Acad. Sci. USA 2010, 107:14229-14234.
12. Guo S., Bai H., Megyola C.M., Halene S., Krause D.S., Scadden D.T., Lu J. Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. Proc. Natl. Acad. Sci. USA 2012, 109:16636-16641.
13. Hafner M., Landthaler M., Burger L., Khorshid M., Hausser J., Berninger P., Rothballer A., Ascano M., Jungkamp A.C., Munschauer M., et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010, 141:129-141.
14. Han Y.C., Park C.Y., Bhagat G., Zhang J., Wang Y., Fan J.B., Liu M., Zou Y., Weissman I.L., Gu H. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J.Exp. Med. 2010, 207:475-489.
15. He Y.F., Li B.Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
16. Hsu C.H., Peng K.L., Kang M.L., Chen Y.R., Yang Y.C., Tsai C.H., Chu C.S., Jeng Y.M., Chen Y.T., Lin F.M., et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012, 2:568-579.
17. Huang X., Schwind S., Yu B., Santhanam R., Wang H., Hoellerbauer P., Mims A., Klisovic R., Walker A.R., Chan K.K., et al. Targeted delivery of microRNA-29b by transferrin conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin. Cancer Res. 2013, 19:2355-2367.
18. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
19. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
20. Kallin E.M., Rodríguez-Ubreva J., Christensen J., Cimmino L., Aifantis I., Helin K., Ballestar E., Graf T. Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol. Cell 2012, 48:266-276.
21. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., An J., Lamperti E.D., Koh K.P., Ganetzky R., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
22. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., Chang T.C., Vivekanandan P., Torbenson M., Clark K.R., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
23. Langemeijer S.M.C., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., Stevens-Linders E., van Hoogen P., van Kessel A.G., Raymakers R.A., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842.
24. Li Z., Cai X., Cai C.L., Wang J., Zhang W., Petersen B.E., Yang F.-C., Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
25. Lian C.G., Xu Y., Ceol C., Wu F., Larson A., Dresser K., Xu W., Tan L., Hu Y., Zhan Q., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
26. Lipchina I., Elkabetz Y., Hafner M., Sheridan R., Mihailovic A., Tuschl T., Sander C., Studer L., Betel D. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes Dev. 2011, 25:2173-2186.
27. Long D., Lee R., Williams P., Chan C.Y., Ambros V., Ding Y. Potent effect of target structure on microRNA function. Nat. Struct. Mol. Biol. 2007, 14:287-294.
28. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N.Engl. J. Med. 2009, 361:1058-1066.
29. Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., Figueroa M.E., Vasanthakumar A., Patel J., Zhao X., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
30. Pronier E., Almire C., Mokrani H., Vasanthakumar A., Simon A., da Costa Reis Monte Mor B., Massé A., Le Couédic J.P., Pendino F., Carbonne B., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555.
31. Quivoron C., Couronné L., Della Valle V., Lopez C.K., Plo I., Wagner-Ballon O., Do Cruzeiro M., Delhommeau F., Arnulf B., Stern M.H., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
32. Shaham L., Binder V., Gefen N., Borkhardt A., Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012, 26:2011-2018.
33. Shih A.H., Abdel-Wahab O., Patel J.P., Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 2012, 12:599-612.
34. Song S.J., Ito K., Ala U., Kats L., Webster K., Sun S.M., Jongen-Lavrencic M., Manova-Todorova K., Teruya-Feldstein J., Avigan D.E., et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87-101.
35. Song S.J., Poliseno L., Song M.S., Ala U., Webster K., Ng C., Beringer G., Brikbak N.J., Yuan X., Cantley L.C., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
36. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
37. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
38. Varambally S., Cao Q., Mani R.-S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
39. Wu H., Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011, 25:2436-2452.
40. Wu Y., Guo Z., Liu Y., Tang B., Wang Y., Yang L., Du J., Zhang Y. Oct4 and the small molecule inhibitor, SC1, regulates Tet2 expression in mouse embryonic stem cells. Mol. Biol. Rep. 2013, 40:2897-2906.
41. Yang H., Liu Y., Bai F., Zhang J.Y., Ma S.H., Liu J., Xu Z.D., Zhu H.G., Ling Z.Q., Ye D., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32:663-669.
42. Zhang P., Huang B., Xu X., Sessa W.C. Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem. Biophys. Res. Commun. 2013, 437:368-373.